2007
DOI: 10.1016/j.ijantimicag.2006.10.009
|View full text |Cite
|
Sign up to set email alerts
|

High prevalence of SHV-12 and the emergence of CTX-M-12 in clinical isolates of Klebsiella pneumoniae from Korea

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2007
2007
2014
2014

Publication Types

Select...
5

Relationship

1
4

Authors

Journals

citations
Cited by 5 publications
(2 citation statements)
references
References 6 publications
0
2
0
Order By: Relevance
“…CTX-M-12 ESBL differs from CTX-M-3 by three amino acid substitutions and has a high level of hydrolytic activity against cefotaxime compared with ceftazidime [13]. Since CTX-M-12 was first reported in K. pneumoniae isolates from Kenya in 2001 [13], and subsequently in Colombia in 2002 [26], it has been detected in clinical isolates from E. coli, K. pneumoniae, and Proteus mirabilis in Korea [2,3,23,24]. All of the isolates in this present study concomitantly produced TEM-1 beta-lactamase.…”
Section: Molecular Characterization Of Esbl Genesmentioning
confidence: 99%
“…CTX-M-12 ESBL differs from CTX-M-3 by three amino acid substitutions and has a high level of hydrolytic activity against cefotaxime compared with ceftazidime [13]. Since CTX-M-12 was first reported in K. pneumoniae isolates from Kenya in 2001 [13], and subsequently in Colombia in 2002 [26], it has been detected in clinical isolates from E. coli, K. pneumoniae, and Proteus mirabilis in Korea [2,3,23,24]. All of the isolates in this present study concomitantly produced TEM-1 beta-lactamase.…”
Section: Molecular Characterization Of Esbl Genesmentioning
confidence: 99%
“…In Korea, the prevalence of extended-spectrum b-lactamases (ESBLs) in clinical Klebsiella pneumoniae isolates has been reported to be 17.7-30.0 % (Jeong et al, 2004;Kim et al, 2005;Ko et al, 2008a). SHV-12 is the most common ESBL in K. pneumoniae isolates from Korean hospitals followed by SHV-31, SHV-32 and TEM-52 and also CTX-M-type ESBLs, CTX-M-3, CTX-M-12, CTX-M-14 and CTX-M-15 (Bae et al, 2007;Jeong et al, 2004;Kim et al, 2005;Ko et al, 2008a;Ryoo et al, 2005). However, most of the previous studies in Korea have been performed on clinical isolates from patients irrespective of whether they cause disease.…”
Section: Introductionmentioning
confidence: 99%